This week's roundup of Houston innovators includes Allie Danziger of Ascent Funding, Adrian Trömel of Rice University, and Michael Suffredini of Axiom Space. Photos courtesy

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from education to space tech — recently making headlines in Houston innovation.


Allie Danziger, senior vice president and general manager of student success at Ascent Funding

Allie Danziger joins the Houston Innovators Podcast to discuss her edtech startup Ampersand's exit. Photo courtesy of Ampersand

For the second time in less than six years, Houston entrepreneur Allie Danziger has navigated a company through an exit. But, with the two exists under her belt, Danziger says the two transactions could not be any more different.

Danziger founded Integrate Agency, a digital-focused public relations firm, in 2009 and sold it to another marketing and PR firm based in Austin in 2018. She founded her next company, Ampersand Professionals, in 2020 to address the challenges for upskilling young professionals to prepare them for success in the workplace — something employers really wanted, but struggled to do consistently.

Last month, Ampersand was acquired by Ascent Funding, a college loan provider that's building out a platform to support its college-aged borrowers. In this week's episode of the Houston Innovators Podcast, Danziger shares how this opportunity came about and looks back on these two pivotal deals. Read more.

Adrian Trömel, assistant vice president for strategy and investments at Rice University's Office of Innovation

In his new role, Adrian Trömel will oversee the creation of the Rice Nexus, an innovation hub within the Ion that aims to bridge the gap between the university and Houston's innovation ecosystem. Photo courtesy of Rice

Rice University’s Office of Innovation has named Houston materials scientist-turned-entrepreneur Adrian Trömel as its new assistant vice president for strategy and investments.

Trömel founded non-invasive neurostimulation medical device company CNX Medical at the Texas Medical Innovation Institute in 2019 and most recently served as chief growth officer for Hamilton Health Box, which brings an on-site care team to company offices.

In his new role, Trömel will oversee the creation of the Rice Nexus, an innovation hub within the Ion that aims to bridge the gap between the university and Houston's innovation ecosystem. He will also lead the creation of a translational research grant fund and a university-affiliated venture fund for Rice-affiliated entrepreneurs. Read more.

Michael Suffredini, CEO and president of Axiom Space

Axiom Space CEO Michael Suffredini has announced the company's series C round with support from Aljazira Capital. Photo courtesy of Axiom Space

Houston has another unicorn — a company valued at $1 billion or more — thanks to a recent round of funding.

Axiom Space released the news this week that it's closed its series C round of funding to the tune of $350 million. While the company didn't release its valuation, it confirmed to Bloomberg that it's over the $1 billion threshold. Axiom reports that, according to available data, it's now raised the second-most funding of any private space company in 2023 behind SpaceX.

Saudi Arabia-based Aljazira Capital and South Korea-based Boryung Co. led the round. To date, Axiom has raised over $505 million with $2.2 billion in customer contracts, according to the company.

“We are honored to team with investors like Aljazira Capital, Boryung and others, who are committed to realizing the Axiom Space vision,” Axiom Space CEO and president Michael Suffredini says in a news release. “Together, we are working to serve innovators in medicine, materials science, and on-orbit infrastructure who represent billions of dollars in demand over the coming decade. Read more.

Axiom Space CEO Michael Suffredini (right) has announced the company's series C round with support from Aljazira Capital, led by CEO Naif AlMesned. Photo courtesy of Axiom Space

Houston space tech startup raises $350M series C, clinches unicorn status

$1B club

Houston has another unicorn — a company valued at $1 billion or more — thanks to a recent round of funding.

Axiom Space released the news this week that it's closed its series C round of funding to the tune of $350 million. While the company didn't release its valuation, it confirmed to Bloomberg that it's over the $1 billion threshold. Axiom reports that, according to available data, it's now raised the second-most funding of any private space company in 2023 behind SpaceX.

Saudi Arabia-based Aljazira Capital and South Korea-based Boryung Co. led the round. To date, Axiom has raised over $505 million with $2.2 billion in customer contracts, according to the company.

“We are honored to team with investors like Aljazira Capital, Boryung and others, who are committed to realizing the Axiom Space vision,” Axiom Space CEO and president Michael Suffredini says in a news release. “Together, we are working to serve innovators in medicine, materials science, and on-orbit infrastructure who represent billions of dollars in demand over the coming decade.

"We are building on the legacy of the International Space Station, leveraging the pillars that were constructed in low-Earth orbit more than two decades ago, to now support a burgeoning global space economy,” he continues.

Axiom, founded in 2016 by Suffredini and Executive Chairman Kam Ghaffarian, is working on the first commercial space station that will replace the International Space Station when NASA retires it in 2031. The first module is expected to launch to the ISS by 2026.

Boryung, which has reportedly invested in Axiom prior to this round, is a firm focused on health care investments. Chairman of the firm, Jay Kim, says Boryung is making investments in technology that supports human space missions and building a space health care system.

“We recognize the depth of human spaceflight knowledge and the level of space station construction and management experience at Axiom Space, as well as the sophistication of the company’s sales and business strategy,” Kim says in the release. “We have a shared vision and ethos and are excited to build opportunity together.”

Naif AlMesned, CEO and managing director of Aljazira Capital, says his investment in Axiom is in accordance with Saudi Vision 2030, a government program launched in 2016 by the Kingdom of Saudi Arabia to increase economic, cultural, and social diversification for the sovereign state.

“We believe in the importance of innovation in various sectors and across various markets," AlMesned says in the release. "In line with the Saudi Vision 2030’s transformative approach, we acknowledge the need for technology toward the advancement of human life. To that end, we are excited to support Axiom Space along its journey of building for beyond.”

In addition to its work on Axiom Station, the company is working on other contracts with NASA, including constructing a new age spacesuit, a long-term NASA contract that's reported to be $1.26 billion. Axiom has also collaborated with NASA on two private astronaut missions — with two more planned for 2024.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston-area lab grows with focus on mobile diagnostics and predictive medicine

mobile medicine

When it comes to healthcare, access can be a matter of life and death. And for patients in skilled nursing facilities, assisted living or even their own homes, the ability to get timely diagnostic testing is not just a convenience, it’s a necessity.

That’s the problem Principle Health Systems (PHS) set out to solve.

Founded in 2016 in Clear Lake, Texas, PHS began as a conventional laboratory but quickly pivoted to mobile diagnostics, offering everything from core blood work and genetic testing to advanced imaging like ultrasounds, echocardiograms, and X-rays.

“We were approached by a group in a local skilled nursing facility to provide services, and we determined pretty quickly there was a massive need in this area,” says James Dieter, founder, chairman and CEO of PHS. “Turnaround time is imperative. These facilities have an incredibly sick population, and of course, they lack mobility to get the care that they need.”

What makes PHS unique is not only what they do, but where they do it. While they operate one of the largest labs serving skilled nursing facilities in the state, their mobile teams go wherever patients are, whether that’s a nursing home, a private residence or even a correctional facility.

Diagnostics, Dieter says, are at the heart of medical decision-making.

“Seventy to 80 percent of all medical decisions are made from diagnostic results in lab and imaging,” he says. “The diagnostic drives the doctor’s or the provider’s next move. When we recognized a massive slowdown in lab results, we had to innovate to do it faster.”

Innovation at PHS isn’t just about speed; it’s about accessibility and precision.

Chris Light, COO, explains: “For stat testing, we use bedside point-of-care instruments. Our phlebotomists take those into the facilities, test at the bedside, and get results within minutes, rather than waiting days for results to come back from a core lab.”

Scaling a mobile operation across multiple states isn’t simple, but PHS has expanded into nine states, including Texas, Oklahoma, Kansas, Missouri and Arizona. Their model relies on licensed mobile phlebotomists, X-ray technologists and sonographers, all trained to provide high-level care outside traditional hospital settings.

The financial impact for patients is significant. Instead of ambulance rides and ER visits costing thousands, PHS services often cost just a fraction, sometimes only tens or hundreds of dollars.

“Traditionally, without mobile diagnostics, the patient would be loaded into a transportation vehicle, typically an ambulance, and taken to a hospital,” Dieter says. “Our approach is a fraction of the cost but brings care directly to the patients.”

The company has also embraced predictive and personalized medicine, offering genetic tests that guide medication decisions and laboratory tests that predict cognitive decline from conditions like Alzheimer's and Parkinson’s.

“We actively look for complementary services to improve patient outcomes,” Dieter says. “Precision medicine and predictive testing have been a great value-add for our providers.”

Looking to the future, PHS sees mobile healthcare as part of a larger trend toward home-based care.

“There’s an aging population that still lives at home with caretakers,” Dieter explains. “We go into the home every day, whether it’s an apartment, a standalone home, or assisted living. The goal is to meet patients where they are and reduce the need for hospitalization.”

Light highlighted another layer of innovation: predictive guidance.

“We host a lot of data, and labs and imaging drive most treatment decisions,” Light says. “We’re exploring how to deploy diagnostics immediately based on results, eliminating hours of delay and keeping patients healthier longer.”

Ultimately, innovation at PHS isn’t just about technology; it’s about equity.

“There’s an 11-year life expectancy gap between major metro areas and rural Texas,” Dieter says. “Our innovation has been leveling the field, so everyone has access to high-quality diagnostics and care, regardless of where they live.”

Aegis Aerospace appoints Houston space leader as new president

moving up

Houston-based Aegis Aerospace's current chief strategy officer, Matt Ondler, will take on the additional role of president on Jan. 1. Ondler will succeed Bill Hollister, who is retiring.

“Matt's vision, experience, and understanding of our evolving markets position us to build on our foundation and pursue new frontiers,” Stephanie Murphy, CEO of Aegis Aerospace, said in a news release.

Hollister guided Aegis Aerospace through expansion and innovation in his three years as president, and will continue to serve in the role of chief technology officer (CTO) for six months and focus on the company's technical and intellectual property frameworks.

"Bill has played an instrumental role in shaping the success and growth of our company, and his contributions leave an indelible mark on both our culture and our achievements," Murphy said in a news release.

Ondler has a background in space hardware development and strategic leadership in government and commercial sectors. Ondler founded subsea robots and software company Houston Mechatronics, Inc., now known as Nauticus Robotics, and also served as president, CTO and CSO during a five-year tenure at Axiom Space. He held various roles in his 25 years at NASA and was also named to the Texas Aerospace Research and Space Economy Consortium Executive Committee last year.

"I am confident that with Matt at the helm as president and Bill supporting us as CTO, we will continue to build on our strong foundation and further elevate our impact in the space industry," Murphy said in a news release. "Matt's vision, experience, and understanding of our evolving markets position us to build on our foundation and pursue new frontiers."

Rice University launches new center to study roots of Alzheimer’s and Parkinson’s

neuro research

Rice University launched its new Amyloid Mechanism and Disease Center last month, which aims to uncover the molecular origins of Alzheimer’s, Parkinson’s and other amyloid-related diseases.

The center will bring together Rice faculty in chemistry, biophysics, cell biology and biochemistry to study how protein aggregates called amyloids form, spread and harm brain cells. It will serve as the neuroscience branch of the Rice Brain Institute, which was also recently established.

The team will work to ultimately increase its understanding of amyloid processes and will collaborate with the Texas Medical Center to turn lab discoveries into real progress for patients. It will hold its launch event on Jan. 21, 2026, and hopes to eventually be a launchpad for future external research funding.

The new hub will be led by Pernilla Wittung-Stafshed, a Rice biophysicist and the Charles W. Duncan Jr.-Welch Chair in Chemistry.

“To make a real difference, we have to go all the way and find a cure,” Wittung-Stafshede said in a news release. “At Rice, with the Amyloid Mechanism and Disease Center as a catalyst, we have the people and ideas to open new doors toward solutions.”

Wittung-Stafshede, who was recruited to Rice through a Cancer Prevention and Research Institute of Texas grant this summer, has led pioneering work on how metal-binding proteins impact neurodegenerative disorders, including Alzheimer’s and Parkinson’s diseases. Her most recent study, published in Advanced Science, suggests a new way of understanding how amyloids may harm cells and consume the brain’s energy molecule, ATP.

According to Alzheimer’s Disease International, neurodegenerative disease cases could reach around 78 million by 2030 and 139 million by 2050. Wittung-Stafshede’s father died of dementia several years ago.

“This is close to my heart,” Wittung-Stafshede added in the news release. “Neurodegenerative diseases such as dementia, Alzheimer’s and Parkinson’s are on the rise as people live longer, and age is the largest risk factor. It affects everyone.”